How the Artificial Pancreas Has Evolved for Diabetes Care

What Was Studied and Why It Matters

Decades ago, a landmark study called the Diabetes Control and Complications Trial (DCCT) proved something that changed diabetes care forever: keeping blood sugar levels well-controlled dramatically lowers the risk of serious complications like kidney disease, nerve damage, and vision loss. But tighter control also raised the risk of dangerous low blood sugars (hypoglycemia). So researchers went to work finding smarter ways to manage glucose — without putting patients in harm's way.

A 2025 review published in the Journal of Diabetes Science and Technology by Bergenstal, Heller, and Breton traces the full journey of that work — from the first finger-stick glucose meters to today's sophisticated automated insulin delivery (AID) systems, and previews what the future may hold.

What the Research Found

From Finger Sticks to Continuous Glucose Monitoring

The first major leap forward was continuous glucose monitoring (CGM). Thanks to advances in sensor chemistry — specifically "wired enzyme" technology — devices could finally measure glucose levels in real time, around the clock, without requiring constant finger sticks. This eventually led to the first factory-calibrated CGM, meaning no more manual calibrations with finger-stick readings.

Connecting CGM to an Insulin Pump: The Closed Loop

The next breakthrough was linking CGM data directly to an insulin pump. A built-in algorithm reads your glucose trends and automatically adjusts how much insulin is delivered — speeding up delivery when glucose rises and pulling back when it drops. This is what's known as an automated insulin delivery (AID) system, sometimes called a "closed-loop" or artificial pancreas system. Several AID systems are now approved in the United States, and the review provides a helpful breakdown of each — covering pump type, how the algorithm works, the connected data platform, and who each system is approved for.

New Ways to Deliver Insulin

Researchers are also exploring alternatives to under-the-skin insulin delivery. One promising approach involves an implantable pump that delivers insulin directly into the abdominal cavity (intraperitoneal delivery), which may more closely mimic how the body's own pancreas works.

Beyond Glucose: Smarter Sensors on the Horizon

Future systems may go further by adding sensors that continuously measure ketones, lactate, or even insulin levels in the blood — not just glucose. This extra information could help the system respond even more precisely, moving closer to a truly autonomous artificial pancreas.

What This Means for Real Patients

If you or someone you care for uses an insulin pump or CGM, this research shows how far the technology has come — and how much more refined it continues to become. Today's AID systems already reduce hypoglycemia risk and improve time-in-range compared to traditional pump or injection therapy.

Staying stocked with the right CGM sensors and pump supplies is essential to getting the most from these systems. MDS Diabetes makes it easy to manage your supplies so your device never misses a beat.

Bottom Line

Automated insulin delivery systems — combining continuous glucose monitors with smart insulin pumps — represent one of the biggest advances in diabetes management since the DCCT trial. Current systems are already helping people spend more time in a healthy glucose range with less risk of dangerous lows. And with sensors that may soon track ketones and insulin levels too, the artificial pancreas is getting smarter every year.